Business
Contract wins
Contract wins.
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\n17 August 2023\n \nAptamer Group plc\n \nContract wins\n \nAptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces signing of two new contracts with a top five pharma partner valued up to £219,000.\n \nThese two contracts represent further conversion of the sales pipeline announced previously. The final value to be recognised as revenue for these new contracts will be subject to scientific and commercial attrition as the contracts progress, which is scheduled to be completed over the course of the current financial year.\n \nThe first contract is for the development of an Optimer pair to a neurodegenerative biomarker for use in an immunoassay platform. The second contract is a follow-on contract for the final stage of Optimer development to a neuronal protein target for immunohistochemistry (IHC), following positive results in the earlier stages of Optimer development. This builds on the adoption of our Optimer-Fc platform for use in automated IHC workflows.\n \nOptimer binders are being sought as alternatives to traditional antibodies for analytical assays to enable increased accuracy and selectivity in the detection of validated biomarkers, while the extended target range of Optimer binders compared with antibodies enables the generation of reagents to novel biomarkers.\n \nDr Rob Quinn, CEO of Aptamer Group, said: \"I am pleased to be able to extend our partnership with this top five pharma partner. These two projects are further evidence of the need for Optimer binders to meet challenging requirements for use in real-world applications when, to date, antibodies have been unable to provide a satisfactory solution, such as IHC. Building awareness and adoption of Optimer technology by such partners is key to allowing us to deliver on our strategy of executing therapeutic, diagnostic, and bioprocessing licensing deals.\"\n \n \n \n- ENDS -\n \nFor further information, please contact:\n \n \n\n\n\nAptamer Group plc\nDr Rob Quinn\n\n\n+44 (0) 1904 217 404\n\n\n\n\nSPARK Advisory Partners Limited - Nominated Adviser \nAndrew Emmott / Mark Brady / Adam Dawes\n\n\n+44 (0) 20 3368 3550\n\n\n\n\nTurner Pope Investments (TPI) Limited - Broker \n...